NYSE:NVO

Novo Nordisk A/s Stock News

Healthcare > Biotechnology

Buy NVO

*Your capital is at risk

$47.64

+0.230 (+0.485%)

At Close: Jun 25, 2026

The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline - NVO

05:45am, Thursday, 06'th Feb 2025

NEW YORK , Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

04:12am, Thursday, 06'th Feb 2025

Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated

Shareholders that Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky about Pending Class Action - NVO

08:30pm, Wednesday, 05'th Feb 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders

04:45pm, Wednesday, 05'th Feb 2025

NVO DEADLINE NOTIFICATION: A Class Action Lawsuit was filed against Novo Nordisk -- Investors are Urged to Contact BFA Law before March 25 Deadline

04:18pm, Wednesday, 05'th Feb 2025

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE:NVO) and certain of the Co

Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

03:15pm, Wednesday, 05'th Feb 2025

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply impro

Novo Nordisk CEO expects same growth for 2025

02:40pm, Wednesday, 05'th Feb 2025

Novo Nordisk (NVO) shares gain after the pharmaceutical company's earnings beat on the bottom and top lines despite warnings of slower growth. Novo Nordisk CEO Lars Fruergaard Jørgensen sits down wit

Why Novo Nordisk Stock Is Soaring Today

02:28pm, Wednesday, 05'th Feb 2025

Shares of Novo Nordisk (NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m.

Novo Nordisk Has Probably Declined Enough

01:58pm, Wednesday, 05'th Feb 2025

Novo Nordisk A/S's recent 44% decline combined with impressive Q4 2024 and fiscal 2024 results with strong sales and profit growth raise the question if the company is a “Buy” again. The company's

Novo Nordisk CEO shares his outlook for Wegovy pricing in the U.S.

01:30pm, Wednesday, 05'th Feb 2025

Novo Nordisk CEO Lars Fruergaard Jørgensen discusses pricing on Wegovy prescriptions.

Contact Levi & Korsinsky by March 25, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)

12:45pm, Wednesday, 05'th Feb 2025

Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman

12:32pm, Wednesday, 05'th Feb 2025

SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects of its

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by